![]() |
|
|
Vol. 29, Issue 11, 1460-1466, November 2001
State University of New York, Upstate Medical University,
Department of Pediatrics, Syracuse, New York (A.-K.S., M.K.A., O.A.S.,
S.K., P.D.S., R.L.D.); University of California, San Diego, Department
of Chemistry and Biochemistry, La Jolla, California (R.C.F., G.L.N.);
and Saint Justine Hospital, Department of Hematology Oncology,
Montreal, Quebec, Canada (M.L.B.)
The Pediatric Oncology Group study for metastatic Ewing's sarcoma
used amifostine and mesna with the alkylating agents. To determine the
fate of combined drug thiols, we measured thiol levels in plasma, red
blood cells (RBC), and peripheral blood mononuclear cells (PBMC) of
four patients. We also conducted analogous measurements on two patients
who received mesna alone and a volunteer's blood following in vitro
treatment. Thiols were labeled with monobromobimane, separated on
high-pressure liquid chromatography, and detected by
fluorescence. Incubation of a volunteer's blood with mesna, WR-1065,
or both revealed that cellular uptake of total reducible drug was
~10% of plasma level for mesna but ~60% for WR-1065. Cellular
drugs were mainly the thiol form, whereas half of the plasma drugs were
disulfides. Combined incubation with both thiols did not change the
extent or form of uptake. WR-1065 and mesna prevented glutathione
depletion by 4-hydroperoxycyclophosphamide. Results from patients were
similar. WR-1065 and mesna appeared in the cells by the end of the drug
infusions, although WR-1065 uptake was more efficient than mesna. The
concentration-time profiles of mesna in RBC paralleled those in plasma.
Amifostine administration during mesna infusion caused transient
increase in mesna levels. Both agents increased blood cysteine and
decreased total reducible cysteine. Mesna alone and mesna plus
amifostine prevented cellular glutathione depletion. In conclusion,
mesna is imported by RBC and PBMC, but less efficiently than WR-1065.
When present at equal levels, these thiols do not influence each
other's uptake. Adequate dosing of either drug is necessary for
protecting the cells from toxic effects of alkylating agents.
This article has been cited by other articles:
![]() |
B. L. Urquhart, D. J. Freeman, J. D. Spence, and A. A. House Mesna as a Nonvitamin Intervention to Lower Plasma Total Homocysteine Concentration: Implications for Assessment of the Homocysteine Theory of Atherosclerosis J. Clin. Pharmacol., August 1, 2007; 47(8): 991 - 997. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Bernstein, M. Devidas, D. Lafreniere, A.-K. Souid, P. A. Meyers, M. Gebhardt, K. Stine, R. Nicholas, E. J. Perlman, R. Dubowy, et al. Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--A Report From the Children's Oncology Group J. Clin. Oncol., January 1, 2006; 24(1): 152 - 159. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-K. Souid, R. L. Dubowy, S. M. Blaney, L. Hershon, J. Sullivan, W. D. McLeod, and M. L. Bernstein Phase I Clinical and Pharmacologic Study of Weekly Cisplatin and Irinotecan Combined with Amifostine for Refractory Solid Tumors Clin. Cancer Res., February 1, 2003; 9(2): 703 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid Oncologist, October 1, 2002; 7(5): 393 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Sadowitz, B. A. Hubbard, J. C. Dabrowiak, J. Goodisman, K. A. Tacka, M. K. Aktas, M. J. Cunningham, R. L. Dubowy, and A.-K. Souid Kinetics of Cisplatin Binding to Cellular DNA and Modulations by Thiol-Blocking Agents and Thiol Drugs Drug Metab. Dispos., February 1, 2002; 30(2): 183 - 190. [Abstract] [Full Text] [PDF] |
||||